# CORE Biomedicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/core-biomedicine

- Industry: Biotechnology
- Headquarters: Allston, US
- Website: www.corebiomedicine.com/
- Total disclosed funding: $21M
- Latest round: Series A (Jul 28, 2026)
- Investors on record: 9

## About

CORE Biomedicine, Inc., develops innovative therapies targeting core lineage pathways essential for tumor survival, aiming to advance treatment options for oncology patients. Founded in 2022 and based in Massachusetts, US, CORE Biomedicine, Inc. focuses on creating therapies that address key mechanisms in tumor survival. The company was co-founded by Ping Zhu (CEO) and Douglas McMillin. In July 2026, CORE Biomedicine, Inc. raised USD 21 million in series A funding co-led by UTokyo Innovation Platform and Elikon Venture, with participation from InnoPinnacle Fund, Mitsubishi UFJ Capital, Suzhou Capital Group, CD Capital, YuanBio Venture, Root Venture, and Vision Incubate. The round was part of larger series A and grant funding.

CORE Biomedicine, Inc. specializes in developing therapies that focus on core lineage pathways critical for tumor survival and aim to disrupt dysfunctional cell signaling linked to tumor growth, specifically for luminal cancers such as bladder, pancreatic, gastric, and colorectal tumors. Their products are geared towards clinical settings in North America and Asia, targeting healthcare providers for oncology patients.

CORE Biomedicine, Inc. generates revenue through strategic partnerships and collaborations with pharmaceutical and biotechnology sectors, utilizing a lineage therapy-based drug discovery platform. Its business transactions typically include licensing agreements and clinical trial partnerships, yielding upfront payments, milestone payments, and royalties from product sales post-commercialization.

The company will use the July 2026 funding to advance its primary programs, emphasizing discovery initiatives and moving into the initial stages of clinical development.

## Funding rounds

- Series A, Jul 28, 2026, $21M — Mitsubishi UFJ Capital, Root Ventures, YuanBio Venture, CD Capital, UTokyo Innovation Platform, Elikon Venture, InnoPinnacle Fund, Vision Incubate, Suzhou Capital Group
- Seed, Mar 14, 2025 — UTokyo Innovation Platform

## Investors

- UTokyo Innovation Platform (https://capitalatlas.ai/funds/utokyo-innovation-platform) — Seed, Series A
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A
- Root Ventures (https://capitalatlas.ai/funds/root-ventures) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- CD Capital — Series A
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Series A
- InnoPinnacle Fund — Series A
- Vision Incubate (https://capitalatlas.ai/funds/vision-incubate) — Series A
- Suzhou Capital Group — Series A